Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
暂无分享,去创建一个
J. Verweij | J. Schellens | G. Stoter | J. Verweij | G. Stoter | J. H. Schellens | J. Ma | H. J. Kolker | H. E. van Ingen | H. V. van Ingen | J. Ma | J. Schellens | HE van Ingen | HJ Kolker
[1] J. da Silva,et al. Drug-related chromosomal changes in chemoresistant human ovarian carcinoma cells. , 1989, Cancer genetics and cytogenetics.
[2] Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck. , 1992, British journal of clinical pharmacology.
[3] N. Vogelzang. Continuous infusion chemotherapy: a critical review. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] K. Jabboury,et al. Cis‐diamminedichloroplatinum (II) by 5‐day continuous infusion a new dose schedule with minimal toxicity , 1984, Cancer.
[5] C. Kovacs,et al. Proliferative defects in renal and intestinal epithelium after cis-dichlorodiammine platinum (II). , 1982, British journal of cancer.
[6] H. Pinedo,et al. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. , 1983, European journal of cancer & clinical oncology.
[7] P. Lohman,et al. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. , 1984, Cancer research.
[8] S. Ito,et al. Multiple and irreversible binding of cis-diamminedichloroplatinum(II) to human serum albumin and its effect on warfarin binding. , 1991, Chemical & pharmaceutical bulletin.
[9] J. da Silva,et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.
[10] D. Bajorin,et al. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. , 1986, Cancer research.
[11] S. Steinberg,et al. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. , 1990, Cancer research.
[12] G Milano,et al. Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. , 1992, European journal of cancer.
[13] H. Pinedo,et al. Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. , 1982, European journal of cancer & clinical oncology.
[14] J. Bertino,et al. 24‐Hour infusion of cis‐platinum in head and neck cancers , 1978, Cancer.
[15] P A Dekker-de Kiefte,et al. Diagnosis and Treatment , 2020, Diabetes.